vs
Side-by-side financial comparison of EXELIXIS, INC. (EXEL) and GEO GROUP INC (GEO). Click either name above to swap in a different company.
GEO GROUP INC is the larger business by last-quarter revenue ($708.4M vs $598.7M, roughly 1.2× EXELIXIS, INC.). EXELIXIS, INC. runs the higher net margin — 40.8% vs 4.5%, a 36.4% gap on every dollar of revenue. On growth, GEO GROUP INC posted the faster year-over-year revenue change (16.6% vs 5.6%). EXELIXIS, INC. produced more free cash flow last quarter ($332.4M vs $-153.6M). Over the past eight quarters, EXELIXIS, INC.'s revenue compounded faster (18.7% CAGR vs 8.1%).
Exelixis, Inc. is a genomics-based drug discovery company located in Alameda, California, and the producer of Cometriq, a treatment approved by the U.S. Food and Drug Administration (FDA) for medullary thyroid cancer with clinical activity in several other types of metastatic cancer.
The GEO Group, Inc. (GEO) is a publicly traded C corporation headquartered in Boca Raton, Florida, that invests in private prisons and mental health facilities in the United States, Australia, South Africa, and the United Kingdom. The company's facilities include immigration detention centers, minimum security detention centers, and mental-health and residential-treatment facilities. GEO also operates government-owned facilities pursuant to management contracts. As of September 30, 2024, the ...
EXEL vs GEO — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $598.7M | $708.4M |
| Net Profit | $244.5M | $31.8M |
| Gross Margin | 95.6% | — |
| Operating Margin | 39.3% | 11.8% |
| Net Margin | 40.8% | 4.5% |
| Revenue YoY | 5.6% | 16.6% |
| Net Profit YoY | 74.8% | 105.1% |
| EPS (diluted) | $0.89 | $0.16 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $598.7M | — | ||
| Q4 25 | $597.8M | $708.4M | ||
| Q3 25 | $568.3M | $682.3M | ||
| Q2 25 | $555.4M | $636.2M | ||
| Q1 25 | $566.8M | $604.6M | ||
| Q4 24 | — | $607.7M | ||
| Q3 24 | $539.5M | $603.1M | ||
| Q2 24 | $637.2M | $607.2M |
| Q1 26 | $244.5M | — | ||
| Q4 25 | $193.6M | $31.8M | ||
| Q3 25 | $184.8M | $173.9M | ||
| Q2 25 | $159.6M | $29.1M | ||
| Q1 25 | $139.9M | $19.6M | ||
| Q4 24 | — | $15.5M | ||
| Q3 24 | $118.0M | $26.3M | ||
| Q2 24 | $226.1M | $-32.5M |
| Q1 26 | 95.6% | — | ||
| Q4 25 | 96.9% | — | ||
| Q3 25 | 96.6% | — | ||
| Q2 25 | 96.5% | — | ||
| Q1 25 | 96.5% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 96.8% | — | ||
| Q2 24 | 97.2% | — |
| Q1 26 | 39.3% | — | ||
| Q4 25 | 39.6% | 11.8% | ||
| Q3 25 | 37.6% | 6.0% | ||
| Q2 25 | 33.6% | 11.3% | ||
| Q1 25 | 28.8% | 10.1% | ||
| Q4 24 | — | 11.2% | ||
| Q3 24 | 25.2% | 13.7% | ||
| Q2 24 | 43.3% | 13.2% |
| Q1 26 | 40.8% | — | ||
| Q4 25 | 32.4% | 4.5% | ||
| Q3 25 | 32.5% | 25.5% | ||
| Q2 25 | 28.7% | 4.6% | ||
| Q1 25 | 24.7% | 3.2% | ||
| Q4 24 | — | 2.5% | ||
| Q3 24 | 21.9% | 4.4% | ||
| Q2 24 | 35.5% | -5.4% |
| Q1 26 | $0.89 | — | ||
| Q4 25 | $0.69 | $0.16 | ||
| Q3 25 | $0.65 | $1.24 | ||
| Q2 25 | $0.55 | $0.21 | ||
| Q1 25 | $0.47 | $0.21 | ||
| Q4 24 | — | $0.14 | ||
| Q3 24 | $0.40 | $0.19 | ||
| Q2 24 | $0.77 | $-0.25 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.1B | $69.0M |
| Total DebtLower is stronger | — | $1.7B |
| Stockholders' EquityBook value | $2.2B | $1.5B |
| Total Assets | $2.8B | $3.8B |
| Debt / EquityLower = less leverage | — | 1.11× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $1.1B | — | ||
| Q4 25 | $988.5M | $69.0M | ||
| Q3 25 | $791.1M | $183.9M | ||
| Q2 25 | $1.0B | $67.9M | ||
| Q1 25 | $1.1B | $64.8M | ||
| Q4 24 | — | $76.9M | ||
| Q3 24 | $1.2B | $70.6M | ||
| Q2 24 | $1.0B | $46.3M |
| Q1 26 | — | — | ||
| Q4 25 | — | $1.7B | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $1.7B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | $2.2B | — | ||
| Q4 25 | $2.2B | $1.5B | ||
| Q3 25 | $2.0B | $1.5B | ||
| Q2 25 | $2.1B | $1.4B | ||
| Q1 25 | $2.2B | $1.3B | ||
| Q4 24 | — | $1.3B | ||
| Q3 24 | $2.3B | $1.3B | ||
| Q2 24 | $2.1B | $1.3B |
| Q1 26 | $2.8B | — | ||
| Q4 25 | $2.8B | $3.8B | ||
| Q3 25 | $2.7B | $3.8B | ||
| Q2 25 | $2.8B | $3.7B | ||
| Q1 25 | $2.9B | $3.6B | ||
| Q4 24 | — | $3.6B | ||
| Q3 24 | $3.0B | $3.6B | ||
| Q2 24 | $2.8B | $3.6B |
| Q1 26 | — | — | ||
| Q4 25 | — | 1.11× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 1.31× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $333.5M | $-117.3M |
| Free Cash FlowOCF − Capex | $332.4M | $-153.6M |
| FCF MarginFCF / Revenue | 55.5% | -21.7% |
| Capex IntensityCapex / Revenue | 0.2% | 5.1% |
| Cash ConversionOCF / Net Profit | 1.36× | -3.69× |
| TTM Free Cash FlowTrailing 4 quarters | $875.8M | $-124.9M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $333.5M | — | ||
| Q4 25 | $290.3M | $-117.3M | ||
| Q3 25 | $49.0M | $79.6M | ||
| Q2 25 | $211.4M | $39.2M | ||
| Q1 25 | $240.3M | $71.2M | ||
| Q4 24 | — | $18.5M | ||
| Q3 24 | $271.3M | $109.3M | ||
| Q2 24 | $119.5M | $31.2M |
| Q1 26 | $332.4M | — | ||
| Q4 25 | $288.8M | $-153.6M | ||
| Q3 25 | $46.2M | $-14.1M | ||
| Q2 25 | $208.5M | $2.4M | ||
| Q1 25 | $236.3M | $40.5M | ||
| Q4 24 | — | $-2.3M | ||
| Q3 24 | $263.1M | $90.5M | ||
| Q2 24 | $113.0M | $6.8M |
| Q1 26 | 55.5% | — | ||
| Q4 25 | 48.3% | -21.7% | ||
| Q3 25 | 8.1% | -2.1% | ||
| Q2 25 | 37.5% | 0.4% | ||
| Q1 25 | 41.7% | 6.7% | ||
| Q4 24 | — | -0.4% | ||
| Q3 24 | 48.8% | 15.0% | ||
| Q2 24 | 17.7% | 1.1% |
| Q1 26 | 0.2% | — | ||
| Q4 25 | 0.2% | 5.1% | ||
| Q3 25 | 0.5% | 13.7% | ||
| Q2 25 | 0.5% | 5.8% | ||
| Q1 25 | 0.7% | 5.1% | ||
| Q4 24 | — | 3.4% | ||
| Q3 24 | 1.5% | 3.1% | ||
| Q2 24 | 1.0% | 4.0% |
| Q1 26 | 1.36× | — | ||
| Q4 25 | 1.50× | -3.69× | ||
| Q3 25 | 0.27× | 0.46× | ||
| Q2 25 | 1.32× | 1.35× | ||
| Q1 25 | 1.72× | 3.64× | ||
| Q4 24 | — | 1.19× | ||
| Q3 24 | 2.30× | 4.15× | ||
| Q2 24 | 0.53× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
EXEL
| Cabometyx | $544.7M | 91% |
| Collaboration | $52.1M | 9% |
| Collaborative Arrangementwith Takeda | $5.9M | 1% |
| Cometriq | $1.8M | 0% |
GEO
| Us Corrections And Detention | $498.0M | 70% |
| Electronic Monitoring And Supervision Services | $83.7M | 12% |
| Reentry Services | $72.2M | 10% |
| AU | $49.1M | 7% |
| ZA | $5.4M | 1% |
